Baylor, GE Medical Launch ‘The Health Channel’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

HOUSTON-GE Medical Systems and Baylor College of Medicine have launched a 24-hour satellite programming service to deliver accredited, continuing education for physicians, nurses, and other allied health professionals directly to hospitals.

HOUSTON—GE Medical Systems and Baylor College of Medicine have launched a 24-hour satellite programming service to deliver accredited, continuing education for physicians, nurses, and other allied health professionals directly to hospitals.

The new service, called The Health Channel, is directed by Baylor College of Medicine and Texas Children’s Hospital, and is available through GE Medical Systems’ TiP-TV satellite broadcast network. Currently, 1,600 health care facilities in the US, Canada, and Europe provide TiP-TV programming to their staff.

Programs are developed and accredited by Baylor in cooperation with a consortium of leading academic medical institutions, including The Cleveland Clinic Foundation, Duke University Medical Center, the Mayo Clinic, M.D. Anderson Cancer Center, and others.

Programs repeat frequently to accommodate various day and night staff schedules. The channel runs 24 hours a day, 7 days a week, with new programming offered every week. A bi-monthly broadcast guide lists dates and times.

The monthly subscription rate for The Health Channel varies depending on hospital bed size and can range from $750 to $3,000. Hospitals can subscribe by calling toll free 1-877-GE TiPTV (1-877-438-4788). More information on the new service is available at the Channel’s website, www.healthchannelweb.com.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.